

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
14 April 2005 (14.04.2005)

PCT

(10) International Publication Number
WO 2005/032482 A2

(51) International Patent Classification⁷: **A61K**

Stephanie [US/US]; 1239 Hopkins Avenue, Palo Alto, CA 94301 (US). **GARREN, Hideki** [US/US]; 417 E. Meadow Drive, Palo Alto, CA 94306 (US).

(21) International Application Number:
PCT/US2004/032598

(22) International Filing Date: 1 October 2004 (01.10.2004)

(74) Agents: **BASTIAN, Kevin, L.** et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/508,350 3 October 2003 (03.10.2003) US

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): **BAY-HILL THERAPEUTICS, INC.** [US/US]; Suite 201, 3430 West Bayshore Road, Palo Alto, CA 94303 (US).



(72) Inventors; and

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(75) Inventors/Applicants (for US only): **BROOME,**

[Continued on next page]

(54) Title: TREATMENT OF DEMYELINATING AUTOIMMUNE DISEASE WITH MODIFIED ORDERED PEPTIDES



(57) Abstract: Compositions and methods are provided for the treatment of demyelinating autoimmune disease. Therapeutic doses are administered of a combination of therapeutic ordered peptides or one or more modified therapeutic ordered peptide(s) comprising amino acids representing a consensus sequence of a protein identified as a target of the autoimmune T and B cell response. Of particular interest are therapeutic ordered peptides of the target proteins in multiple sclerosis, for example the myelin proteins MBP, MOG, PLP, MAG and cyclic nucleotide phosphodiesterase. The therapeutic ordered peptide may consist only of the ordered repeats, or may be extended at either termini by the addition of other D- or L- amino acid residues. For therapy, the therapeutic ordered peptides may be administered topically or parenterally, by injection at a particular site, including subcutaneously, intraperitoneally, intravascularly, or the like or transdermally, as by electrotransport. The subject methods are used for prophylactic or therapeutic purposes. The compositions of the invention may also contain other therapeutically active agents, immunomodulators, immunosuppressants, β -interferon, steroids, statins etc.



GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.